Top Markets
#1 ADO Protocol ADO Protocol +329.52%
#2 GoPlus Security GoPlus Security +53.72%
#3 Nockchain Nockchain +47.20%
#4 Starpower Starpower +36.50%
#5 Tutorial Tutorial +35.69%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +31.73%
#7 The Black Bull The Black Bull +29.67%
#8 GAIB AID GAIB AID +24.67%
#9 Casper Network Casper Network +21.80%
#10 Verus Coin Verus Coin +20.40%
Coin of the day
ADO Protocol ADO Protocol
Inställningar
Språk
SVENSKA
Valuta
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Rankning i aktier #32693
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Aktiekurs
$1.54
Marknadsvärde
$9.35M
Förändring (1 dag)
-3.14%
Förändring (1 år)
-58.71%
Land
GB
Handel NuCana plc (NCNA)

Kategori

Healthcare
EPS för NuCana plc (NCNA)
EPS per 2026 TTM: 0
Enligt NuCana plcs senaste finansiella rapporter och aktiekurs är bolagets nuvarande EPS (TTM) 0. Vid slutet av 2026 hade bolaget ett EPS på 0, lika med EPS från 2026 som var 0.
EPS-historik för NuCana plc från 2026 till 2026
EPS vid slutet av varje år
År EPS Ändra
Inte tillräckligt med data för de angivna datumen.
EPS för liknande företag eller konkurrenter
Företag EPS EPS-differens Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $13.70 -
BE